Objective
The cell cycle is a complex process that is highly regulated by cyclin-dependent kinases (CDKs). CDKs function at different phases of the cell cycle and are regulated by their association with specific cofactors, the cyclins. Different cyclins exhibit distinct expression patterns that contribute to the temporal coordination of each cell cycle event.
Two forms of cyclin A exist in mammals. Cyclin A2 is ubiquitously expressed, and activates CDK2 or CDK1 kinases to promote both S phase progression and G2/M transition, respectively. In contrast, cyclin A1 pairs with CDK1 only, and is present in germ cells undergoing meiosis in the testis.
The essential role of cyclin A1 in meiosis was confirmed by the observation that cyclin A1-deficient male germ cells arrest a t the G2/M transition of meiotic prophase I and exhibit some apoptotic phenotypes. Cyclin A2 whose expression is more ubiquitous, is essential for embryonic development, the null embryos dying at around day 5.5 pc.
This early embryonic lethality has prevented the elucidation of cyclin A2 function in whole mammalian organisms. In order to address the physiological role of cyclin A2 in mammalian growth and health, we will generate mouse models with tissue-specific and/or time-specific inactivation of cyclin A 2.
This mouse model will serve as natural readouts of the regulation and function of cyclin A2 in life and growth of a mammalian organism, and will provide several useful cellular models for cell cycle studies. Cyclin A2 over-expression causes premature cell cycle entry into the S phase and over-expression of cyclin A2 was shown to promote cellular transformation.
However, the precise role of cyclin A2 in the cell transformation process, and in the development of cancer is not known. We wish to address the impact of cyclin A2 deletion on cellular transformation in vitro and cancer incidence in vivo, the ultimate goal being to determine whether inhibitors of cyclin A2 could improve cancer treatment.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences developmental biology
- medical and health sciences medical biotechnology cells technologies stem cells
- medical and health sciences clinical medicine oncology
- medical and health sciences basic medicine physiology
- medical and health sciences clinical medicine embryology
You need to log in or register to use this function
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP6-2004-MOBILITY-12
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
IRG - Marie Curie actions-International re-integration grants
Coordinator
MONTPELLIER
France
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.